Phenotypic Classification of Multisystem Inflammatory Syndrome in Children Using Latent Class Analysis.

Publication date: Jan 02, 2025

Multisystem inflammatory syndrome in children (MIS-C) is an uncommon but severe hyperinflammatory illness that occurs 2 to 6 weeks after SARS-CoV-2 infection. Presentation overlaps with other conditions, and risk factors for severity differ by patient. Characterizing patterns of MIS-C presentation can guide efforts to reduce misclassification, categorize phenotypes, and identify patients at risk for severe outcomes. To characterize phenotypic clusters of MIS-C and identify clusters with increased clinical severity. In this cohort study, MIS-C phenotypic clusters were inferred using latent class analysis applied to the largest cohort to date of cases from US national surveillance data from 55 US public health jurisdictions. Cases reported to the Centers for Disease Control and Prevention MIS-C national surveillance program as of April 4, 2023, with symptom onset on or before December 31, 2022, were retrospectively analyzed. Twenty-nine clinical signs and symptoms were selected for clustering after excluding variables with 20% or more missingness and 10% or less or 90% or more prevalence. A total of 389 cases missing 10 or more variables were excluded, and multiple imputation was conducted on the remaining cases. Differences by cluster in prevalence of each clinical sign and symptom, percentage of patients admitted to the intensive care unit (ICU), length of hospital and ICU stay, mortality, and relative frequency over time. Among 8944 included MIS-C cases (median [IQR] patient age, 8. 7 [5. 0-12. 5] years; 5407 [60. 5%] male), latent class analysis identified 3 clusters characterized by (1) frequent respiratory findings primarily affecting older children (respiratory cluster; 713 cases [8. 0%]; median [IQR] age, 12. 7 [6. 3-16. 5] years), (2) frequent shock and/or cardiac complications (shock and cardiac cluster; 3359 cases [37. 6%]; median [IQR] age, 10. 8 [7. 7-14. 0] years), and (3) remaining cases (undifferentiated cluster; 4872 cases [54. 5%]; median [IQR] age, 6. 8 [3. 6-10. 3] years). The percentage of patients with MIS-C admitted to the ICU was highest for the shock and cardiac cluster (82. 3% [2765/3359]) followed by the respiratory (49. 5% [353/713]) and undifferentiated clusters (33. 0% [1609/4872]). Among patients with data on length of stay available, 129 of 632 hospitalizations (20. 4%) and 54 of 281 ICU stays (19. 2%) in the respiratory cluster lasted 10 or more days compared with 708 of 3085 (22. 9%) and 157 of 2052 (7. 7%), respectively, in the shock and cardiac cluster and 293 of 4467 (6. 6%) and 19 of 1220 (1. 6%), respectively, in the undifferentiated cluster. The proportion of cases in both the respiratory cluster and the shock and cardiac cluster decreased after emergence of the Omicron variant in the US. In this cohort study, MIS-C cases clustered into 3 subgroups with distinct clinical phenotypes, severity, and distribution over time. Use of clusters in future studies may support efforts to evaluate surveillance case definitions and identify groups at highest risk for severe outcomes.

Open Access PDF

Concepts Keywords
April Adolescent
Hospitalizations Child
Inflammatory Child, Preschool
Cohort Studies
COVID-19
Female
Humans
Infant
Latent Class Analysis
Male
Phenotype
Retrospective Studies
Risk Factors
SARS-CoV-2
United States

Semantics

Type Source Name
disease MESH Multisystem Inflammatory Syndrome in Children
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease IDO symptom
disease MESH shock
disease MESH complications
disease MESH Infectious Diseases
disease MESH Syndrome
drug DRUGBANK Methylphenidate
drug DRUGBANK Naproxen
drug DRUGBANK Azelaic acid
disease MESH Kawasaki disease
disease MESH toxic shock syndrome
disease MESH death
disease MESH acute respiratory distress syndrome
drug DRUGBANK Methionine
disease MESH obesity
disease MESH malformations
disease MESH pneumonia
disease MESH chest pain
disease MESH comorbidity
drug DRUGBANK Nesiritide
disease MESH arrhythmia
disease MESH myocarditis
disease MESH pericarditis
disease MESH Seizures
disease IDO immunosuppression
disease MESH fetal alcohol syndrome
disease MESH Ehlers Danlos syndrome
disease MESH achondroplasia
disease MESH chromosomal abnormalities
disease MESH Morbidity
disease MESH left ventricular dysfunction
disease IDO algorithm
disease MESH critically ill
disease MESH Respiratory Diseases
disease IDO process
disease MESH Allergy
disease MESH Asthma
pathway KEGG Asthma
disease MESH emergency
drug DRUGBANK L-Aspartic Acid

Original Article

(Visited 3 times, 1 visits today)